Want to see GLUE full AI Analyst Report?
GLUE Stock Chart & Stats
$14.38
$0.07(0.31%)
At close: 4:00 PM EDT
$14.38
$0.07(0.31%)
Day’s Range― - ―
52-Week Range$8.94 - $25.77
Previous CloseN/A
Volume570.68K
Average Volume (3M)1.37M
Market Cap
$909.44M
Enterprise Value$1.87B
Total Cash (Recent Filing)$621.10M
Total Debt (Recent Filing)$37.99M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 05, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding85,313,400
10 Day Avg. Volume1,630,245
30 Day Avg. Volume1,370,009
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)4.41
Price to Sales (P/S)8.31
P/FCF Ratio-37.37
Enterprise Value/Market Cap2.06
Enterprise Value/Revenue65.19
Enterprise Value/Gross Profit70.14
Enterprise Value/Ebitda-12.02
Forecast
1Y Price Target
$26.86Price Target Upside86.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$67.80M
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressStrong Phase 1 results provide evidence that Monte Rosa’s molecular glue approach can produce target engagement, disease-relevant biomarker improvements and tolerability in humans. These findings support advancement into multiple Phase 2 indications and strengthen the platform’s long-term development potential.
Partnered Pipeline ValidationThe Novartis-led Phase 2a/b launch validates MRT-6160 beyond early clinical testing while transferring trial execution and funding responsibility to a major partner. The $50 million payment and potential milestone, royalty and profit-sharing economics improve the pipeline’s strategic and financial value.
Conservative LeverageLow debt relative to equity gives Monte Rosa a comparatively conservative capital structure and greater flexibility than a highly leveraged biotechnology company. This balance-sheet capacity can help support continued clinical development and reduce the immediate pressure from borrowing costs while programs mature.
Bears Say
Revenue ContractionThe sharp revenue decline shows that reported commercial or partnered income remains volatile, while the large net loss indicates expenses materially exceed the current revenue base. Sustained weakness would limit internal funding capacity and leave future operating progress dependent on pipeline milestones or external capital.
Continued Cash BurnNegative operating and free cash flow mean the company is not yet self-funding its development activities. Although burn improved versus the prior period, continued cash consumption can reduce financial flexibility over time and maintain reliance on milestone receipts, partnerships or additional funding.
Severe UnprofitabilityVery negative returns on equity demonstrate that the current business is destroying value on its invested capital rather than generating sustainable returns. If losses persist, accumulated deficits may gradually weaken the equity cushion and constrain the company’s ability to finance a broad clinical pipeline internally.
Monte Rosa Therapeutics News
GLUE FAQ
What was Monte Rosa Therapeutics’s price range in the past 12 months?
Monte Rosa Therapeutics lowest stock price was $8.94 and its highest was $25.77 in the past 12 months.
What is Monte Rosa Therapeutics’s market cap?
Monte Rosa Therapeutics’s market cap is $909.44M.
When is Monte Rosa Therapeutics’s upcoming earnings report date?
Monte Rosa Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 16 days.
How were Monte Rosa Therapeutics’s earnings last quarter?
Monte Rosa Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.05.
Is Monte Rosa Therapeutics overvalued?
According to Wall Street analysts Monte Rosa Therapeutics’s price is currently Undervalued.
Does Monte Rosa Therapeutics pay dividends?
Monte Rosa Therapeutics does not currently pay dividends.
What is Monte Rosa Therapeutics’s EPS estimate?
Monte Rosa Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Monte Rosa Therapeutics have?
Monte Rosa Therapeutics has 85,313,400 shares outstanding.
What happened to Monte Rosa Therapeutics’s price movement after its last earnings report?
Monte Rosa Therapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went up 0.641%.
Which hedge fund is a major shareholder of Monte Rosa Therapeutics?
Currently, no hedge funds are holding shares in GLUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monte Rosa Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.86 (86.77% Upside)
$26.86 (86.77% Upside)
Blogger Sentiment
Bullish
GLUE Sentiment 75%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $220.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 14.4%
Last 30 Days ▲ 14.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.06%
12-Months-Change
Fundamentals
Return on Equity
-43.31%
Trailing 12-Months
Asset Growth
92.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
GLUE Stock 12 Month Forecast
Average Price Target
$26.86
▲(86.77% Upside)
Technical Analysis
Kura Oncology
―
Arvinas Holding Company
―
C4 Therapeutics
―
Alumis Inc.
―
Odyssey Therapeutics, Inc.
―
Ownership Overview
8.88% Insiders
14.97% Mutual Funds
0.22% Other Institutional Investors
60.13% Public Companies and
Individual Investors